Advertisement
New Zealand markets close in 1 hour 5 minutes

  • NZX 50

    11,799.37
    -75.98 (-0.64%)
     

  • NZD/USD

    0.5926
    +0.0006 (+0.11%)
     

  • NZD/EUR

    0.5547
    +0.0005 (+0.10%)
     

  • ALL ORDS

    7,905.00
    +44.00 (+0.56%)
     

  • ASX 200

    7,648.80
    +43.20 (+0.57%)
     

  • OIL

    82.87
    +0.18 (+0.22%)
     

  • GOLD

    2,389.10
    +0.70 (+0.03%)
     

  • NASDAQ

    17,493.62
    -220.04 (-1.24%)
     

  • FTSE

    7,847.99
    +27.63 (+0.35%)
     

  • Dow Jones

    37,753.31
    -45.66 (-0.12%)
     

  • DAX

    17,770.02
    +3.79 (+0.02%)
     

  • Hang Seng

    16,462.04
    +210.20 (+1.29%)
     

  • NIKKEI 225

    38,161.92
    +200.12 (+0.53%)
     

  • NZD/JPY

    91.3980
    +0.1100 (+0.12%)
     

Biogen Inc. (BIIB) Stock Moves -1.06%: What You Should Know

Zacks Equity Research
·3-min read

In the latest trading session, Biogen Inc. (BIIB) closed at $222.31, marking a -1.06% move from the previous day. This change was narrower than the S&P 500's 1.22% loss on the day. Meanwhile, the Dow lost 0.19%, and the Nasdaq, a tech-heavy index, lost 0.53%.

Heading into today, shares of the company had lost 4.06% over the past month, outpacing the Medical sector's loss of 11.24% and the S&P 500's loss of 6.58% in that time.

Biogen Inc. will be looking to display strength as it nears its next earnings release, which is expected to be February 3, 2022. The company is expected to report EPS of $3.34, down 27.07% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.62 billion, down 8.08% from the year-ago period.

It is also important to note the recent changes to analyst estimates for Biogen Inc.Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

ADVERTISEMENT

Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.36% lower. Biogen Inc. currently has a Zacks Rank of #3 (Hold).

Digging into valuation, Biogen Inc. currently has a Forward P/E ratio of 11.82. This represents a discount compared to its industry's average Forward P/E of 17.36.

Also, we should mention that BIIB has a PEG ratio of 1.13. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BIIB's industry had an average PEG ratio of 1.08 as of yesterday's close.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 162, which puts it in the bottom 37% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Biogen Inc. (BIIB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research